Vaccinex
Update in progressVCNX (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vaccinex is a clinical-stage biotechnology company focusing on targeted biotherapeutics for cancer, neurodegenerative and autoimmune diseases. Its lead candidate, pepinemab, is a humanized anti-SEMA4D antibody in phase 2 for Alzheimer's disease and has completed phase 2 for Huntington's disease; it is being studied in various phase 2 combos with pembrolizumab, avelumab, nivolumab/ipilimumab, and trastuzumab/dendritic cell vaccines. It also develops ActivMAb, CHS-114, anti-CCR8, and VX5 (preclinical). Partnerships include Merck, Ares, Emory, Huntington Study Group, Catalent and Surface Oncology. Founded 2001, Rochester, NY.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- -0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCPK (PNK)
- LocationUnited States
- CEODr. Maurice Zauderer Ph.D.
- Founded2001
- Employees23
- Websitewww.vaccinex.com
Identifiers
- ISINUS9186401033
- FIGIBBG00469NFK4
- CUSIP918640103
- CIK0001747866